Annovis Bio enters securities purchase agreement for $1.025M common stock offering

Annovis Bio, Inc.

Sold 114,911 shares at $8.92/share to institutional investor for gross proceeds of $1,025,000.
Issued under effective shelf registration statement on Form S-3 (333-276814) effective Feb 12, 2024.
Closing expected promptly after conditions satisfied, including NYSE listing of the shares.
30-day lock-up restricts additional equity issuances, warrant amendments, and variable rate transactions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at aggregate gross proceeds of $1,025,000 (effective 2024-03-15).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: aggregate gross proceeds of $1,025,000
Effective: 2024-03-15

Exact text from the filing

On March 15, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-035082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.